Data for Rivaroxaban presented at the ACC Scientific Sessions 2012
March 24 - 27, 2012
Chicago, IL, USA
Findings from the Phase III EINSTEIN-PE study were presented in the Late-Breaking Clinical Trials Session on March 26th, 2012, 08:00 – 09:30 a.m. CDT, at the American College of Cardiology’s 61st Annual Scientific Sessions (ACC) in Chicago, USA, by lead investigator Harry R. Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.
On this occasion we hosted a conference call for investors and analysts on March 26, 2012 at approx. 5:00 p.m. CEST (3:00 p.m. GMT).
Bayer's Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE StudyRivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine more
Monday, March 26: Investor Conference Call on Rivaroxaban
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations